Why the study?
Complications of acute MI carry extremely high mortality, leaving critical evidence gaps in current therapeutic management as targets for subsequent research.
This review highlights the need for individualized and novel approaches based on pathobiology to manage complications of acute myocardial infarction, given the non-improving mortality trends.
Stagnant post-MI complication mortality warrants clinical caution with current strategies; leaves open pathobiology-driven individualized approaches for prospective trials.
Mechanical reperfusion with primary angioplasty, as the treatment of choice in acute myocardial infarction (MI), is associated not only with a high percentage of full epicardial and tissue reperfusion but also with a very good immediate and long-term clinical outcome. However, the Achilles heel of MI treatment is its ensemble of complications, such as cardiogenic shock due to severe systolic and/or diastolic dysfunction or MI mechanical complications, including perforation of the left ventricular free wall, papillary muscle rupture with acute mitral regurgitation and ventricular septal rupture. They are associated with an increased or, sometimes, with an extremely high mortality rate, determining the overall mortality in an MI patient population. In this review we summarize the mechanisms of MI complications, current therapeutic management and alternative directions for overcoming their devastating consequences. Moreover, we have sought to indicate gaps in the evidence on current treatments as the potential targets for further clinical research. From the perspective of mortality trends that are not improving, the forthcoming therapeutic management of complicated MI will require an individualized and novel approach based on their thorough pathobiology.
No takes yet. Share an insight, caveat, or question.
Zalewski et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: